Multiple Sclerosis

intravenous infusion line

Shorter Ocrelizumab Infusion Time for Multiple Sclerosis Does Not Affect Safety Profile

No notable difference in reactions with two-hour infusion in ENSEMBLE PLUS substudy

23-NEU-3534432-CQD-Hero-1-650×450 (1)

It’s Time for a New Framework for Characterizing Multiple Sclerosis

A focus on biological processes should improve both research and management

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

22-NEU-3409067_central-vein-sign_650x450

Central Vein Sign on FLAIR* MRI Comparable to CSF Oligoclonal Bands for Diagnosing MS

Initial pilot study findings suggest a potential reduced need for cerebrospinal fluid testing

22-NEU-3294094-CQD-Hero-650×450

Leveraging Telehealth to Provide Comprehensive Multiple Sclerosis Care

NIH grant supports longitudinal study of clinical, cost and patient/clinician experience outcomes

22-NEU-3222062_mesenchymal-stem-cells_650x450

Phase 2 Trial Hints at Promise of Cellular Therapy for Progressive MS

Single-arm, open-label study offers proof of concept for MSC-NTF cells

22-NEU-2902059_multiple-sclerosis_650x450

Phase 2 Data Show Vidofludimus Calcium Suppresses MRI Lesions in Relapsing MS With Good Tolerability

Selective DHODH inhibitor designed as a better-tolerated alternative to teriflunomide

22-NEU-2798010-CQD-Hero-650×450

Three Standout Investigations at ACTRIMS 2022

Research avenues to keep an eye on in MS and NMOSD diagnostics and therapeutics

22-NEU-2672858_medical-cannabis_650x450

Multiple Sclerosis and Cannabis Use: Where Do Patients Get Their Information?

Survey suggests need for evidence-based education among patients and providers alike

BackPage 2 of 4Next

Advertisement

Ad